Printer Friendly

Potential biomarker for psoriasis severity, treatment efficacy.


The level of serum squamous cell carcinoma antigen 2--an isoform of SCCA that is widely used as a tumor marker for SCC--was significantly higher in both skin and serum of patients with psoriasis, compared with healthy volunteers in a recent study, correlating with psoriasis severity score and reflecting treatment efficacy.

The intensity of skin and serum levels of SCCA2 was correlated in patients with psoriasis, and the study results also suggest that Th17 cytokines (IL-17 and IL-22) induce SCCA2 elevation in serum and skin. "Significant elevation of SCCA2 is associated with disease severity and reflects treatment efficacy. SCCA2 may be a useful biomarker in psoriasis, reflecting Th 17-type inflammation --the main determinant of the severity of psoriasis," wrote Dr. Yuko Watanabe of Yokohama (Japan) City University and associates (Br J Derm. 2016 Jan 29. doi: 10.1111/bjd.14426).

According to the investigators, the commonly used psoriasis area severity index (PASI) is suboptimal because it is not truly quantitative and varies among clinicians. Since there are several new treatment options for psoriasis, including biologies, the authors believe that a new serum marker for psoriasis is needed to evaluate disease activity and manage treatment.

The prospective, cross-sectional study included 123 patients with psoriasis and 25 healthy controls. Serum SCCA2 levels were significantly higher in patients with psoriasis, compared with controls: a median of 2.7 ng/mL versus 0.70 ng/mL, respectively (P less than .0001). Serum SCCA2 levels were positively correlated with PASI for all patients with psoriasis, regardless of subtype. In 38 patients on monotherapy or combination therapy with drugs to treat psoriasis, SCCA2 levels decreased in the 35 patients whose PASI improved on treatment (P less than .0001) and increased in the three cases of clinical deterioration.

The study was supported by a grant from Japan's Ministry of Education, Culture, Sports, Science and Technology. The investigators declared that they had no conflicts of interest.

COPYRIGHT 2016 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Goodman, Alice
Publication:Dermatology News
Date:Mar 1, 2016
Previous Article:Etanercept doubles risk of major malformations.
Next Article:Studies back propranolol for infantile hemangiomas.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters